E-LIB Suche - Ergebnisse für: Ren, Shengxiang

1

Camrelizumab plus famitinib in previously chemo-immunothera..:

Ren, Shengxiang ; Xiong, Anwen ; Yu, Jia...
Cancer Immunology, Immunotherapy. 73 (2024) 7 - p. , 2024

Link: https://doi.org/10.1007/..

2

GPNMB Expression Associates with Inferior Prognosis in Pati..:

Liu, Qian ; Zhang, Jun ; Mao, Shiqi...
Journal of Cancer. 15 (2024) 10 - p. 2960-2970 , 2024

Link: https://doi.org/10.7150/..

3

First-line treatment with camrelizumab plus famitinib in ad..:

Ren, Shengxiang ; Wang, Xicheng ; Han, Bao-Hui...
Journal for ImmunoTherapy of Cancer. 12 (2024) 2 - p. e007227 , 2024

Link: https://doi.org/10.1136/..

4

Efficacy and safety of local ablative therapy for patients ..:

Shao, Chuchu ; Zhi, Xinxin ; Mao, Shiqi...
Thoracic Cancer. 15 (2024) 10 - p. 778-787 , 2024

Link: https://doi.org/10.1111/..

5

Targeting focal adhesion kinase boosts immune response in K..:

Qiao, Meng ; Zhou, Fei ; Liu, Xinyu...
Experimental Hematology & Oncology. 13 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

6

A Phase 1b Study of Ivonescimab, a Programmed Cell Death Pr..:

Wang, Lei ; Luo, Yongzhong ; Ren, Shengxiang...
Journal of Thoracic Oncology. 19 (2024) 3 - p. 465-475 , 2024

Link: https://doi.org/10.1016/..

7

Induction immunochemotherapy followed by definitive chemora..:

Wu, Leilei ; Cheng, Bo ; Sun, Xiaojiang...
MedComm. 5 (2024) 3 - p. , 2024

Link: https://doi.org/10.1002/..

8

Neurocognitive Adverse Events of Lorlatinib: On the Way to ..:

Jia, Keyi ; Ren, Shengxiang
Journal of Thoracic Oncology. 18 (2023) 1 - p. 26-28 , 2023

Link: https://doi.org/10.1016/..

9

Association of PD-L1 expression with efficacy of alectinib ..:

Pan, Yingying ; Liu, Xinyu ; Zhang, Wei...
Lung Cancer. 181 (2023) - p. 107233 , 2023

Link: https://doi.org/10.1016/..

10

Fibronectin promotes tumor angiogenesis and progression of ..:

Zhou, Fei ; Sun, Jianguo ; Ye, Lingyun...
Experimental Hematology & Oncology. 12 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

11

Current status and future perspectives of bispecific antibo..:

Wang, Wanying ; Qiu, Tianyu ; Li, Fei.
Chinese Medical Journal. 136 (2023) 4 - p. 379-393 , 2023

Link: https://doi.org/10.1097/..

12

Outcome comparison of pyrotinib with current standard of ca..:

Mao, Shiqi ; Luo, Libo ; Yang, Shuo...
Chinese Medical Journal. 136 (2023) 7 - p. 848-850 , 2023

Link: https://doi.org/10.1097/..

13

KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs d..:

Ren, Shengxiang ; Feng, Jifeng ; Ma, Shenglin...
International Journal of Cancer. 153 (2023) 3 - p. 623-634 , 2023

Link: https://doi.org/10.1002/..

14

Expert Consensus Recommendations on Biomarker Testing in Me..:

Mitsudomi, Tetsuya ; Tan, Daniel ; Yang, James Chih-Hsin...
Journal of Thoracic Oncology. 18 (2023) 4 - p. 436-446 , 2023

Link: https://doi.org/10.1016/..

15

Molecular correlation of response to pyrotinib in advanced ..:

Mao, Shiqi ; Yang, Shuo ; Liu, Xinyu...
Experimental Hematology & Oncology. 12 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..